(Reuters) -The European Medicines Agency has backed the use of Novo Nordisk’s Wegovy to lower heart risks in overweight or obese adults, the company said on Thursday.
The backing from the European Union’s medicine regulator’s committee comes two days after Wegovy secured the UK regulator’s nod.
Wegovy is also approved for prevention of cardiovascular events in people with obesity in the United States.
Novo said it will implement the updated use of Wegovy on its label, or prescribing information, in the EU within about one month.
(Reporting by Sriparna Roy and Bhanvi Satija in Bengaluru; Editing by Shailesh Kuber and Shinjini Ganguli)
Comments